Buzzelli G, Meacci E, Smorlesi C, Chiarantini E, Birardi A, Gentilini P
Istituto di Clinica Medica Generale e Terapia Medica IV, Università degli Studi di Firenze, Italy.
Chemioterapia. 1987 Aug;6(4):306-9.
Patients affected by liver cirrhosis with and without hepatocellular carcinoma (HCC) underwent galactose testing for the assessment of both quantitative liver function and effective blood flow. The galactose elimination capacity (GEC), when investigating the former parameter, resulted in being significantly reduced in cirrhotics (29.5%) and in cirrhotics with HCC (42.9%) when compared to controls. The galactose clearance, expressing the effective blood flow through the liver, showed a significant decrease (34.0%) only in the group with superimposed HCC. Our results pointed out a significant impairment of effective hepatic blood flow and an overall reduction of hepatic metabolic activity in the cirrhotics with HCC. These data suggest that lower amounts of chemotherapeutic agents must be given to patients affected by cirrhosis with HCC, especially when dealing with substances mainly metabolized by the liver. On the basis of our results, such a reduction was evaluated to be around 50% of the total dosage.
患有和未患有肝细胞癌（HCC）的肝硬化患者均接受了半乳糖检测，以评估肝功能定量和有效血流量。在研究前一个参数时，与对照组相比，肝硬化患者（29.5%）和伴有HCC的肝硬化患者（42.9%）的半乳糖清除能力（GEC）显著降低。表示通过肝脏的有效血流量的半乳糖清除率仅在伴有HCC的组中显著降低（34.0%）。我们的结果指出，伴有HCC的肝硬化患者的有效肝血流量显著受损，肝脏代谢活性总体降低。这些数据表明，对于患有HCC的肝硬化患者，必须给予较低剂量的化疗药物，尤其是在处理主要由肝脏代谢的物质时。根据我们的结果，这种剂量减少估计约为总剂量的50%。
